AstraZeneca CEO Soriot Speaks on $6.9 Billion Cancer Therapy Deal

AstraZeneca is collaborating with Daiichi Sankyo to develop a promising cancer treatment. The company is confident in the drug's potential to become a standard of care for breast cancer, with applications beyond. AstraZeneca has raised equity to fund the deal and strengthen its financial position, aiming for rapid growth. The company remains focused on its R&D pipeline while exploring M&A opportunities to enhance its oncology leadership.

What are the expected applications of the new drug beyond breast cancer?

Why did Astra Zeneca raise additional equity for the deal?